Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jul 10:12:1512784.
doi: 10.3389/fcvm.2025.1512784. eCollection 2025.

Case Report: Practice of whole-course pharmaceutical care: a case in hypertrophic cardiomyopathy and a review of the pharmacist's role

Liu-Cheng Li #  1   2 , Su Zhang #  2 , Jia-Bin Sun #  2   3 , Yao-Yao Xu  2   4 , Kai-Li Mao  5
Affiliations
Case Reports

Case Report: Practice of whole-course pharmaceutical care: a case in hypertrophic cardiomyopathy and a review of the pharmacist's role

Liu-Cheng Li et al. Front Cardiovasc Med. .

Abstract

Clinical pharmacists supported clinicians in medication planning and health education for a male patient diagnosed with hypertrophic cardiomyopathy (HCM). Therapeutically, diltiazem was replaced with metoprolol to further alleviate symptoms. Whole-blood exon sequencing revealed a pathogenic mutation in the beta-myosin heavy chain gene (MYH7, OMIM #160760), consistent with dominant inheritance. Furthermore, low-intensity exercise and screening of the patient's children were recommended. In addition, we provided an overview of current therapeutic approaches, emphasizing potential novel agents and non-pharmaceutical interventions for HCM management. This is the first case report to highlight not only updates in HCM treatment but also the pharmacist's role in long-term HCM management.

Keywords: diltiazem; hypertrophic cardiomyopathy; metoprolol; pharmaceutical care; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Conventional drugs and promising precision treatment for HCM. ASO, antisense oligonucleotide; HCM, hypertrophic cardiomyopathy; NDHP-CCB, non-dihydropyridine calcium channel blockers; shRNA, short hairpin RNA.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Li G, Jin L, Weng Z, Jin X, Lin X, Chen S. Clinical utility of electrocardiographic voltage parameters for the diagnosis of hypertrophic cardiomyopathy. Front Cardiovasc Med. (2024) 11:1354364. 10.3389/fcvm.2024.1354364 - DOI - PMC - PubMed
    1. Ma H, Zhou Y, He Y, Yu C, Liao Q, Xi H, et al. Prognosis for patients with apical hypertrophic cardiomyopathy: a multicenter cohort study based on propensity score matching. Kardiol Pol. (2023) 81(12):1247–56. 10.33963/v.kp.98355 - DOI - PubMed
    1. Xu W, Zhu F, Zhang Y, Li P, Sheng Y. An overview of the treatments for hypertrophic cardiomyopathy. Front Cardiovasc Med. (2024) 11:1387596. 10.3389/fcvm.2024.1387596 - DOI - PMC - PubMed
    1. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. (2022) 79(4):372–89. 10.1016/j.jacc.2021.12.002 - DOI - PubMed
    1. Shafqat A, Shaik A, Koritala S, Mushtaq A, Sabbah BN, Nahid Elshaer A, et al. Contemporary review on pediatric hypertrophic cardiomyopathy: insights into detection and management. Front Cardiovasc Med. (2024) 10:1277041. 10.3389/fcvm.2023.1277041 - DOI - PMC - PubMed

Publication types

LinkOut - more resources